Determinants of chemosensitivity in gastric cancer

Current Opinion in Pharmacology

Volumn 6, Issue 4, 2006, Pages 337-344

  Park, David J ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; ESTERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG SENSITIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHARMACOGENETICS; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; STOMACH CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DIHYDROURACIL DEHYDROGENASE (NADP); DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MUTATION; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; TAXOIDS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 33745686040     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.05.002     Document Type: Review

References (67)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics. CA Cancer J Clin 55 (2005) 74-108
2. Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., Haller D.G., Ajani J.A., Gunderson L.L., Jessup J.M., and Martenson J.A. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
3. Catalano V., Labianca R., Beretta G.D., Gatta G., de Braud F., and Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 54 (2005) 209-241. An outstanding comprehensive review of gastric cancer.
4. Ajani J.A. Evolving chemotherapy for advanced gastric cancer. Oncologist 10 Suppl 3 (2005) 49-58. An outstanding and up-to-date review of chemotherapeutic management of advanced gastric cancer.
5. Lenz H.J., Leichman C.G., Danenberg K.D., Danenberg P.V., Groshen S., Cohen H., Laine L., Crookes P., Silberman H., Baranda J., et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14 (1996) 176-182
6. Yeh K.H., Shun C.T., Chen C.L., Lin J.T., Lee W.J., Lee P.H., Chen Y.C., and Cheng A.L. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82 (1998) 1626-1631
7. Kawakami K., Omura K., Kanehira E., and Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19 (1999) 3249-3252
8. Horie N., Aiba H., Oguro K., Hojo H., and Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20 (1995) 191-197
9. Marsh S., Ameyaw M.M., Githang'a J., Indalo A., Ofori-Adjei D., and McLeod H.L. Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 16 (2000) 528
10. Marsh S., Collie-Duguid E.S., Li T., Liu X., and McLeod H.L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58 (1999) 310-312
11. Iacopetta B., Grieu F., Joseph D., and Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85 (2001) 827-830
12. Pullarkat S.T., Stoehlmacher J., Ghaderi V., Xiong Y.P., Ingles S.A., Sherrod A., Warren R., Tsao-Wei D., Groshen S., and Lenz H.J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1 (2001) 65-70
13. Villafranca E., Okruzhnov Y., Dominguez M.A., Garcia-Foncillas J., Azinovic I., Martinez E., Illarramendi J.J., Arias F., Martinez Monge R., Salgado E., et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19 (2001) 1779-1786
14. Marsh S., McKay J.A., Cassidy J., and McLeod H.L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19 (2001) 383-386
15. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D., Groshen S., and Lenz H.J. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17 (2002) 46-49
16. Ishida Y., Kawakami K., Tanaka Y., Kanehira E., Omura K., and Watanabe G. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 22 (2002) 2805-2809
17. Mandola M.V., Stoehlmacher J., Muller-Weeks S., Cesarone G., Yu M.C., Lenz H.J., and Ladner R.D. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63 (2003) 2898-2904. The first report of a SNP within the TS 5′-UTR tandem repeat polymorphism. This polymorphism has been shown to abolish USF-1 binding and altering transcriptional activation of TS. Thus, TS 5′-UTR polymorphic analysis should incorporate this 'polymorphism within a polymorphism' for more accurate assessment of impact on TS production and function.
18. Kawakami K., and Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63 (2003) 6004-6007. Another report identifying a SNP within the TS 5′-UTR tandem repeat polymorphism. Its incorporation to the TS tandem repeat analysis was able to predict clinical outcome to fluoropyrimidine chemotherapy in patients with colorectal cancer.
19. Mandola M.V., Stoehlmacher J., Zhang W., Groshen S., Yu M.C., Iqbal S., Lenz H.J., and Ladner R.D. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 (2004) 319-327. A report analyzing the functional properties of 6-bp deletion 3′-UTR TS polymorphism. The 6-bp deletion was associated with increased TS mRNA degradation and lower TS expression.
20. Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D.K., and Stoehlmacher J. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br J Cancer 94 (2006) 281-286. A retrospective study evaluating a panel of gene polymorphisms as predictors of clinical outcome to 5-FU-cisplatin chemotherapy in advanced gastric cancer. GSTP1 and TS polymorphisms were shown to be promising predictive markers.
21. Lu J.W., Gao C.M., Wu J.Z., Cao H.X., Tajima K., and Feng J.F. Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet 51 (2006) 155-160. A report of a relatively large number of patients with advanced gastric cancer treated with 5-FU-based therapy assessing the predictive value of TS 3′-UTR 6-bp deletion polymorphism. The 6-bp deletion was associated with superior outcome to chemotherapy.
22. Kawakami K., Graziano F., Watanabe G., Ruzzo A., Santini D., Catalano V., Bisonni R., Arduini F., Bearzi I., Cascinu S., et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 11 (2005) 3778-3783
23. Diasio R.B., and Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16 (1989) 215-237
24. Etienne M.C., Lagrange J.L., Dassonville O., Fleming R., Thyss A., Renee N., Schneider M., Demard F., and Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12 (1994) 2248-2253
25. Lu Z., Zhang R., and Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53 (1993) 5433-5438
26. Johnson M.R., Hageboutros A., Wang K., High L., Smith J.B., and Diasio R.B. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5 (1999) 2006-2011
27. Milano G., et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79 (1999) 627-630
28. Milano G. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 4 (1994) 301-306
29. Wei X. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98 (1996) 610-615
30. Raida M., Schwabe W., Hausler P., Van Kuilenburg A.B., Van Gennip A.H., Behnke D., and Hoffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7 (2001) 2832-2839
31. Takabayashi A., Iwata S., Kawai Y., Kanai M., Taki Y., Takechi T., and Fukushima M. Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int J Oncol 17 (2000) 889-895
32. Toriumi F., Kubota T., Saikawa Y., Yoshida M., Otani Y., Watanabe M., Kumai K., and Kitajima M. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res 24 (2004) 2455-2463
33. Terashima M., Fujiwara H., Takagane A., Abe K., Irinoda T., Nakaya T., Yonezawa H., Oyama K., Saito K., Kanzaki N., et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer 6 Suppl 1 (2003) 71-81
34. Terashima M., Irinoda T., Fujiwara H., Nakaya T., Takagane A., Abe K., Yonezawa H., Oyama K., Inaba T., Saito K., et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22 (2002) 761-768
35. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., and Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7 (2001) 2182-2194
36. Yu J., Shannon W.D., Watson M.A., and McLeod H.L. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 11 (2005) 2053-2062
37. Mathijssen R.H., Marsh S., Karlsson M.O., Xie R., Baker S.D., Verweij J., Sparreboom A., and McLeod H.L. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9 (2003) 3246-3253
38. Humerickhouse R., Lohrbach K., Li L., Bosron W.F., and Dolan M.E. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60 (2000) 1189-1192
39. Iyer L., Hall D., Das S., Mortell M.A., Ramirez J., Kim S., Di Rienzo A., and Ratain M.J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65 (1999) 576-582
40. Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., Fleming G.F., Vokes E.E., Schilsky R.L., and Ratain M.J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2 (2002) 43-47
41. McLeod H.L., Sargent D.J., Marsh S., Fuchs C., Ramanathan R.K., Williamson S., Findlay B., Thibodeau S., Petersen G., and Goldberg R. Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer (CRC): Results from an intergroup trial [abstract 1013]. Proc Am Soc Clin Oncol 22 (2003) 253. A large prospective pharmacogenetic study of patients with advanced colorectal cancer treated with chemotherapy regimens containing 5-FU, irinotecan and oxaliplatin. The reader should refer to the oral presentation available on www.asco.org, which is more up to date than the abstract itself.
42. Johnson N.P., Hoeschele J.D., and Rahn R.O. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 30 (1980) 151-169
43. Reardon J.T., and Sancar A. Molecular mechanism of nucleotide excision repair in mammalian cells. In: Dizdaroglu M., and Karakaya A.E. (Eds). DNA Damage and Repair (1998), Plenum Publishing Corp, New York 377-393
44. Wilson M.D., Ruttan C.C., Koop B.F., and Glickman B.W. ERCC1: a comparative genomic perspective. Environ Mol Mutagen 38 (2001) 209-215
45. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., Groshen S., Salonga D., Cohen H., Laine L., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
46. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., and Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84 (1992) 1512-1517
47. Dabholkar M., Bostick-Bruton F., Yu J.J., and Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
48. Park D, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Zahedy S, Gil J, Mallik N, Lenz H-J: ERCC1 polymorphism is associated with differential ERCC1 mRNA levels. From American Association for Cancer Research's 93rd Annual Meeting: April 6-10, San Francisco, CA, 2002: 1591.
49. Liu D., O'Day S.J., Yang D., Boasberg P., Milford R., Kristedja T., Groshen S., and Weber J. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 11 (2005) 1237-1246
50. Suk R., Gurubhagavatula S., Park S., Zhou W., Su L., Lynch T.J., Wain J.C., Neuberg D., Liu G., and Christiani D.C. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11 (2005) 1534-1538
51. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., Lynch T.J., Su L., and Christiani D.C. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10 (2004) 4939-4943
52. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., Lopez-Vivanco G., Camps C., Botia M., Nunez L., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15 (2004) 1194-1203
53. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., Kim Y.C., and Hwang T.S. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44 (2004) 311-316
54. Viguier J., Boige V., Miquel C., Pocard M., Giraudeau B., Sabourin J.C., Ducreux M., Sarasin A., and Praz F. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11 (2005) 6212-6217
55. Park D.J., Zhang W., Stoehlmacher J., Tsao-Wei D., Groshen S., Gil J., Yun J., Sones E., Mallik N., and Lenz H.J. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1 (2003) 162-166
56. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., Zahedy S., and Lenz H.J. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91 (2004) 344-354
57. Xu Z., Chen Z.P., Malapetsa A., Alaoui-Jamali M., Bergeron J., Monks A., Myers T.G., Mohr G., Sausville E.A., Scudiero D.A., et al. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13 (2002) 511-519
58. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., and Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61 (2001) 8654-8658
59. Oguri T., Fujiwara Y., Katoh O., Daga H., Ishikawa N., Fujitaka K., Yamasaki M., Yokozaki M., Isobe T., Ishioka S., and Yamakido M. Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. Cancer Lett 156 (2000) 93-99
60. Stoehlmacher J., Park D.J., Zhang W., Groshen S., Tsao-Wei D.D., Yu M.C., and Lenz H.J. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94 (2002) 936-942
61. Hohaus S., Di Ruscio A., Di Febo A., Massini G., D'Alo F., Guidi F., Mansueto G., Voso M.T., and Leone G. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 11 (2005) 2175-2179
62. Shu X.O., Gao Y.T., Cai Q., Pierce L., Cai H., Ruan Z.X., Yang G., Jin F., and Zheng W. Genetic polymorphisms in the TGF-β 1 gene and breast cancer survival: a report from the shanghai breast cancer study. Cancer Res 64 (2004) 836-839
63. Kamazawa S., Kigawa J., Kanamori Y., Itamochi H., Sato S., Iba T., and Terakawa N. Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86 (2002) 171-176
64. Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., and Goldstein J.A. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 (2001) 597-607
65. Henningsson A., Marsh S., Loos W.J., Karlsson M.O., Garsa A., Mross K., Mielke S., Vigano L., Locatelli A., Verweij J., et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11 (2005) 8097-8104
66. Ruzzo A., Graziano F., Kawakami K., Watanabe G., Santini D., Catalano V., Bisonni R., Canestrari E., Ficarelli R., Menichetti E.T., et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24 (2006) 1883-1891
67. Marsh S., and McLeod H.L. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5 (2004) 835-843